top of page


CME Series Feature:
Series 1: “Contemporary Multidisciplinary Management of Breast Cancer.”
Sereis 2: Immuno-Oncology Bootcamp For The Oncologist

Education Program 2018


Our Mission: Bringing together the top academic physicians and thought leaders in the world with practicing community clinicians to create an environment for high-level interaction in order to obtain up-to-date medical knowledge to benefit patients. Learning is patient-centered and case-based to maximize the translation of medical knowledge to clinical practice.

We are offering two medical education series for 2018: “Contemporary Multidisciplinary Management of Breast Cancer” and "Immuno-Oncology Bootcamp for the Oncologist.”  


  1. Contemporary Multidisciplinary Management of Breast Cancer: As opposed to monotonous lectures on single topics, each session will open with an actual clinical presentation ranging from topics of early stage breast cancer to advanced, metastatic breast cancer with several types of breast tumors reviewed. The multidisciplinary team will be composed of world leading academic clinician-scientists in breast cancer from the fields of radiology, pathology, surgical oncology, radiation oncology, and medical oncology. Following the discussion of the case, updates of what’s new in these respective fields will be reviewed. Additional lectures depending on scheduling are possible.

  2. Immuno-Oncology Bootcamp for the Oncologist: Is trying to keep up with the emerging but important field of IO giving you a headache? The first of its kind lecture series on all clinical aspects of IO as it relates to several different types of cancer is the focus of this series. Not only are the speakers the world-leaders in their fields but in also the same folks who developed the technologies. Each day will open with real world cases and how IO can be implemented into the care plan. Focused lectures from the distinguished faculty will follow.


Accreditation: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Washington School of Medicine designates this live activity for a maximum of 19.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Because this is a dedicated medical education cruise, course participants will have unprecedented access to faculty to probe them with inquiries both during and after the program. The detailed program will be supplied to participants closer to departure date.


Your all-inclusive CME cruise will include ½ day education program followed ½ day tour program at our ports of call

Faculty Series 1

“Contemporary Multidisciplinary Management of Breast Cancer”

1. Breast Imaging, Dr. Wendy DeMartini, Stanford University Medical Center

Section: Chief of Breast Imaging

Subspecialty: Breast MRI


Dr. Wendy DeMartini is Section Chief of Breast Imaging and Professor in the Department of Radiology at Stanford University Medical Center. She joined the department in 2015, after serving as faculty at the University of Wisconsin and University of Washington School Of Medicine. Dr. DeMartini’s work is focused upon high-quality patient care, education, and clinical research.


Her research is directed toward the appropriate evidence-based use of imaging tests to optimize the detection and evaluation of breast cancer. She has served as an investigator on several studies of breast MRI funded by the National Cancer Institute and by the American College of Radiology Imaging Network (ACRIN). Particular research topics have included the development of a pilot tool for predicting the probability of malignancy of breast MRI lesions, assessment of the impact of background parenchymal enhancement (BPE) on breast MRI accuracy, and evaluation of current utilization patterns of breast MRI and other emerging technologies.


Dr. DeMartini is an active member of many professional organizations, including the Radiologic Society of North America (RSNA) and the Society of Breast Imaging (SBI). She was elected as a Fellow in the SBI in 2009, and was recently elected to the SBI Board of Directors.

2. Breast Pathology, Dr. Mara H. Rendi, University of Washington and Seattle Cancer Care Alliance

Clinical Focus: Breast and Gynecologic Pathology

Course director for the University of Washington School of Medicine pathology course and the pathology/histology thread leader throughout the WWAMI region.


Dr. Rendi is a breast and gynecologic pathologist at the University of Washington and Seattle Cancer Care Alliance. In addition, she is the course director for the University of Washington School of Medicine pathology course and the pathology/histology thread leader throughout the WWAMI region. Her research interests include histopathologic features of breast and ovarian cancer that predict recurrence, upgrade and respectability. In addition, she is creating electronic modules for better teaching pathology to medical students in an integrated curriculum.


Dr. Rendi is a board certified anatomic pathologist, a fellow of the College of American Pathologists and is actively involved in the United States and Canadian Academy of Pathology and the Association of Pathology Chairs Undergraduate Medical Education Division

3. Radiation Therapy, Dr. Thomas A Buchholz, The University of Texas MD Anderson Cancer Center, Houston,TX

Executive Vice President & Physician in Chief

Hubert L. Olive Stringer Distinguished Chair in Honor of Sue Gribble Stringer

Tenured Professor, Division of Radiation Oncology


Dr. Buchholz is one of the most renowned oncology physicians in the world. As Physician-in-Chief Dr. Buchholz is responsible for the clinical faculty and operating of MD Anderson's Houston hospital and ambulatory clinics. His academic interests focus on clinical and translational research in breast cancer and radiation oncology. He is responsible for the education and mentoring junior faculty and trainees in clinical care and clinical/translational research.


Dr. Buchholz has published 370 research papers in peer reviewed journals over his career. He is widely recognized as one of the leaders in breast radiation oncology and sits on numerous panels including those of The American Society of Clinical Oncology (ASCO) and American Society for Therapeutic Radiology and Oncology (ASTRO) in developing guidelines to establish community standards of care. He is also a highly regarded investigator on a number of clinical tirals and is a member of the National Cancer Institute’s roster for the National Clinical Trials Network.

4. Breast Surgery, Dr. Kelly K. Hunt, The University of Texas MD Anderson Cancer Center, Houston,TX

Professor, Department of Surgical Oncology, Division of Surgery

Department Chair ad interim, Department of Breast Surgical Oncology

Hamill Foundation Distinguished Professorship in Honor of Dr. Richard G. Martin, Sr., Department of Surgical Oncology


Dr. Hunt is a career academic surgeon whose expertise stretches from patient care to medical education to basic science – a true triple threat. She is widely recognized as one of the pre-eminent voices in surgical oncology internationally having chaired meetings or major plenary sections at all well-recognized general oncology and surgical oncology meetings. She has mentored over 50 post-doctoral research and clinical fellows, many of whom have subsequently also risen to national prominence. She has 488 research articles and counting attributed to her work and research. She sits on the editorial boards of the Journal of Clinical Oncology and other major journals in the field and she serves as reviewer for the New England Journal of Medicine and The Lancet. She is the PI or a named investigator on 9 grants from federal institutes or from philanthropic organizations. No least, she has been named one of the Best Doctors and Best Surgeons in America (Castle Connolly Medical Ltd) for consistently over a decade.

5. Medical Oncology, Dr. V.K. Gadi (Course Chair), University of Washington and Fred Hutchinson Cancer Research Center

Associate Professor of Medicine, Division of Oncology

Associate Member Clinical Research Division and Public Health Sciences

Associate Member, Translational Research Program


Dr. Gadi is an academic medical oncologist specializing in breast cancer. In addition to being regarded a clinical expert with over a 1000 breast cancer patients under his care, he is a noted educator. He has been actively involved in mentoring medical oncology fellows for nearly a decade preparing them for their board certification. He is also a frequent lecturer and is often asked to chair or section-chair many CME events several times a year. His other roles are as a clinical investigator and translational researcher. He is a former medical editorial board member for New York Times Company and former contributor to He was formerly on the speakers bureaus of Celgene, Amgen, and Roche. He is on the editorial board of Chimerism medical journal and serves as a regular reviewer of several top-tier journals including Blood, Lancet, Lancet Oncology, Breast Cancer Research and Treatment, International Journal of Cancer, Clinical Chemistry, Journal of Clinical Investigation.


Dr. Gadi is either the principal investigator or co-investigator on over 30 clinical trials and is a member of the Southwest Oncology Group (SWOG) and the Translational Breast Cancer Research Consortium (TBCRC). His federally funded research laboratory has made fundamental insights on the long-term immunologic effects of pregnancy on future breast cancer risk and in the functional genetic networks driving cancer resistance to standard treatments. He is the chief medical director and one of the founders of Sengine Precision Medicine, Inc – a spin-off of the Fred Hutchinson Cancer Research Center. For his research, he has been numerous prizes including the Mary Kay Ash Research Award, Expedition Inspiration Young Investigator Award, Norman S. Coplan Scholar Award from the Satellite Foundation, The Immunex Scholar Award from Amgen, and the Scholar Award from the Safeway Foundation.

Faculty Series 2

“ Immuno-Oncology Bootcamp For The Oncologist”


1. Dr. Aude Chapuis, University of Washington School of Medicine, Seattle Cancer Care Alliance

Assistant Member, Fred Hutchinson Cancer Research Center
Assistant Professor, University of Washington

Dr. Aude Chapuis is a member of Fred Hutch's Clinical Research Division and is a researcher in the Program in Immunology. Her focus is understanding the factors associated with successful adoptive transfer of immune T cells and improving the outcomes, developing methods that improve the survival, proliferation and anti-tumor activity of infused T-cell products so as to better eliminate tumor targets and clinical strategies to optimally activate T cells in humans. Chapuis is also an attending physician with the Fred Hutch Bone Marrow Transplant Program at the Seattle Cancer Care Alliance.

2.  Dr. Stephen Ansell, MD PhD, Mayo Clinic

Professor of Medicine, Mayo Clinic

Chair, Mayo Clinic Lymphoma Group


Dr. Ansell is focused on understanding the biology of B-cell malignancies (including Hodgkin's lymphoma Waldenstrom's macroglobulinemia and non-Hodgkin's lymphoma) and to explore the role of the tumor microenvironment in supporting cancer cell growth and survival. The goal of his program is to translate this knowledge into new treatment approaches for patients. His laboratory studies T-cell activation and T-cell exhaustion and seeks to understand the role of phagocytic cells in the tumor. His research has contributed to the use of immune checkpoint therapy in lymphomas. He led the clinical trial that resulted in the approval of nivolumab (Opdivo) for Hodgkin's lymphoma.


Dr. Ansell serves as the the chair for the Scientific Advisory Committee of the International Waldenstrom's Macroglobulinemia Foundation. He is the on the editorial board of the Journal of Clinical Oncology and an Associate editor of the American Journal of Hematology. He is a member of the Scientific Committee of the Leukemia & Lymphoma Society.

3. Dr. Andrei Shustov, University of Washington, Seattle Cancer Care Alliance

Associate Professor, Division of Hematology, University of Washington

Associate Member, Fred Hutchinson Cancer Research Center Attending Physician, Seattle Cancer Care Alliance


Dr. Shustov is a world leader in T cell malignancies. He has been involved directly in the clinical development of several novel agents recently approved by the FDA for these hard-to-treat cancers such as T-cell non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's lymphoma, and acute lymphocytic leukemia. He is also president and founder of the T-cell lymphoma and leukemia foundation.


4. Dr. Sasha Stanton, University of Washington, Seattle Cancer Care Alliance

Assistant Member, Fred Hutchinson Cancer Research Center

Assistant Professor, University of Washington

Attending Physician, Seattle Cancer Care Alliance


Dr. Stanton’s research focuses on ductal carcinoma in situ (DCIS), which is the most common pre-malignant breast lesion with over 60,000 women diagnosed each year.  She develops cancer vaccines with the intent to provide long-term protection against both recurrent DCIS and progression to invasive breast cancer. Her previous studies have demonstrated that vaccination against proteins over expressed in DCIS can prevent development of IBC in a laboratory models. She has now begun to translate these findings to develop a vaccine using proteins that are aberrantly over expressed in DCIS and are biologically relevant to disease progression.

5. Dr. Filippo Milano, MD, PHD - Fred Hutchinson Cancer Research Center University of Washington, Seattle Cancer Care Alliance (Course Chair)

Assistant Member Clinical Research Division and Associate Director Cord Blood Transplantation Cord Blood Program Fred Hutchinson Cancer Research Center

Assistant Professor, University of Washington

Attending Physician, Seattle Cancer Care Alliance


Dr. Filippo Milano is the associate director of the Cord Blood Transplant Program and treats patients with acute leukemias and other blood disorders. His research is focused on the use of umbilical cord blood transplantation as a source of stem cells. He has translated his research into clinical practice improvements with the goal to increase the number of patients eligible to be recipients and to improve clinical outcomes for patients undergoing cord blood transplantation. He is one of the developers of non HLA-matched off-the-shelf ex-vivo expanded cord Blood progenitor cell product following myeloablative cord Blood transplantation.


DATES:  October 29, 2018 – November 5, 2018

TOTAL CME CREDITS:  maximum of 19.5 AMA PRA Category 1 Credits™


Embarkation & Disembarkation 

Embarkation (October 29th Passau): Clients will be able to check-in and board in Passau, Germany beginning at 16:00. Guest who arrive earlier may leave their luggage at reception beginning at 13:00 but will not be able to check-in or receive their cabin until 16:00.  Munich Airport is approximately 2 hours travel to the pier. 2 scheduled paid airport transfers will be made available in the late morning and early afternoon.
Disembarkation (November 5th Budapest): Clients will be required to disembark by 9:30a.  We can assist in pre-arranged transfers from boat to local destinations and airports for an additional fee: BUD Airport is approximately 3o minutes from the pier.

Day 1 (October 29)  - Munich > Passau (checking in and relax onboard)
A CME representative will greet you and arrange your transfer to Passau, where you’ll board your luxury Scenic Space-Ship. Raise a toast to the wonderful cruise you have in store at this evening’s welcome reception. 
Day 2  (October 30) – Passau / 1st day of CME
Morning CME, afternoon join your local guide and discover this beautiful Baroque city. 
Day 3 (October 31) - Linz / 2nd day of CME
Morning CME, afternoon take a pleasurable excursion to the medieval Czech town of Cesky Krumlov and discover its World Heritage-listed old city, or journey on to explore beautiful Salzburg, the birthplace of Mozart and the setting for the film, ‘The Sound of Music’. 
Day 4 (November 1) - Melk > Dürnstein / 3rd day of CME
Morning CME, afternoon be guided through Melk’s magnificent 18th century Benedictine Abbey, or if you want to try something more active, cycle along the river from Melk to one of the most enchanting villages in the region, Dürnstein.  As the day ends, unwind in pleasant company in the beautiful Wachau Valley. 
Day 5 (November 2)- Vienna /4th day of CME
Morning CME, afternoon tour the city of Vienna or Schönbrunn Palace. Alternatively, visit the world-renowned Spanish Riding School and either tour the stables or see the famous Lipizzaner Stallions perfecting their skills during their morning exercise program. Or you can taste your way around the local market with your on board chef on our Shop with a Chef tour. Breathe in the opulence and luxury of Palais Liechtenstein while enjoying a glass of fine Austrian Sekt. Then be enthralled by an enchanting private Viennese evening concert featuring the music of Strauss and Mozart. 
Day 6 (November 3) - Bratislava / 5th day of CME
Morning CME, afternoon with your knowledgeable local guide discover this historic city, situated on the banks of the mighty Danube River. 
Day 7 (November 4) - Budapest /6th day of CME
Morning CME, afternoon let our local city guide introduce you to the towns of Buda and Pest. Alternatively, discover the labyrinths of the Hospital in the Rock or relax at the Thermal Baths and Spa. 
Day 8 (November 5) - Budapest 
After breakfast, you’ll be transferred to the airport.


No CME program on October 29, 2018 while checking in at Passau.

Courses occur in the morning.  Afternoons are free for sightseeing activities. 

bottom of page